Celanese Launches VitalDose(TM) Controlled-Release Excipient for the Pharmaceutical Industry

Celanese Launches VitalDose(TM) Controlled-Release Excipient for the Pharmaceutical Industry

 

DALLAS, Nov 05, 2010 (BUSINESS WIRE) -- Celanese Corporation, a global technology and specialty materials company, today announced the launch of VitalDose(TM), an ethylene vinyl acetate (EVA) polymer-based excipient that facilitates drug makers' efforts to develop and commercialize controlled-release pharmaceutical solutions.

VitalDose excipients are based on EVA polymers and offer a wide degree of flexibility in the design of transdermal, subcutaneous implant and mucosal insert dosage forms. VitalDose offers customizable release properties and the potential for new delivery routes to be used in the development of pharmaceutical product line extensions and new concepts.

"By applying Celanese's VitalDose EVA excipient technology, we are helping our customers retain an edge in a competitive marketplace filled with complex challenges," said Mark Murray, general manager of Celanese's EVA Performance Polymers business. "With competition, particularly from generics, on the rise in the pharmaceutical industry, developing innovative dosage forms is now key to retaining a competitive edge in the industry. Developing new routes of administration for existing products, or enhancing the bioavailability of newly developed yet poorly soluble drugs, is an important option that pharmaceutical companies consider as a strategy to maintain the success of their product franchises," said Murray.

"Celanese is investing in new and innovative resources to grow with the evolving pharmaceutical industry and is maximizing the value of that investment by building on its exceptional excipient technology with product development support and regulatory expertise to meet its customers' specialized needs," said Jon Mortimer, chief technology officer, Celanese Office of Strategic Growth. "VitalDose offers a wide degree of flexibility in the design of controlled release dosage solutions and is another example of how Celanese is committed to helping companies realize innovative growth opportunities through advanced product development."

About Celanese

Celanese Corporation is a global technology leader in the production of specialty materials and chemical products which are used in most major industries and consumer applications. Our products, essential to everyday living, are manufactured in North America, Europe and Asia. Known for operational excellence, sustainability and premier safety performance, Celanese delivers value to customers around the globe with best-in-class technologies. Based in Dallas, Texas, the company employs approximately 7,400 employees worldwide and had 2009 net sales of $5.1 billion, with approximately 73% generated outside of North America. For more information about Celanese Corporation and its global product offerings, visit www.celanese.com.

About Celanese EVA Performance Polymers Inc.

The business is a North American leader in developing products and application technology to improve performance, create value and drive innovation in a broad range of industrial and consumer end-use applications including flexible packaging, thermal lamination film, hot melt adhesive, USP class VI medical products and photovoltaic cells. The business has manufacturing facilities in Edmonton, Canada, and is supported by expert technical service. More information about Celanese EVA Performance Polymers Inc. is available at www.celanese-EVA.com.

Forward-Looking Statements

This release may contain "forward-looking statements," which include information concerning the company's plans, objectives, goals, strategies, future revenues or performance, and other information that is not historical information. When used in this release, the words "outlook," "forecast," "estimates," "expects," "anticipates," "projects," "plans," "intends," "believes," and variations of such words or similar expressions are intended to identify forward-looking statements. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the company will realize these expectations or that these beliefs will prove correct.

There are a number of risks and uncertainties that could cause actual results to differ materially from the results expressed or implied in the forward-looking statements contained in this release. These risks and uncertainties include, among other things: market acceptance of our technology discussed above; the impact of technological developments and competition; changes in general economic, business, political and regulatory conditions in the countries or regions in which we operate; unanticipated operational or commercialization difficulties, including failure of facilities or processes to operate in accordance with specifications or expectations; changes in the price and availability of raw materials, commodities and supplies; the ability to pass increases in raw material prices and other costs on to customers; growth in demand for products produced from our technology; compliance and other costs and potential disruption of production due to accidents or other unforeseen events or delays; changes in customer or consumer preferences and demand; adoption of new or different industry or regulatory standards; ability of third parties, including our commercial partners or suppliers, to comply with their commitments to us; changes in the degree of intellectual property and other legal protection afforded to our products and processes; and various other factors discussed in the company's annual and quarterly reports with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it is made, and the company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.

Celanese is a registered trademark of Celanese Corporation and VitalDose is a registered trademark of Celanese International Corporation.

SOURCE: Celanese Corporation


Celanese Corporation
Investor Relations
Andy Green, +1-972-443-4965
Telefax: +1-972-332-9373
[email protected]
or
Media Relations
Travis Jacobsen, +1-972-443-3750
Telefax: +1 972-443-8519
[email protected]

 


Copyright Business Wire 2010

Suggested Articles

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…

Biogen plans to test its SMA drug Spinraza at a higher-than-approved dose as Novartis' rival gene therapy Zolgensma picks up traction.